|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2008-1-7
|
|
pubmed:abstractText |
Erythropoietin (EPO) has been shown to protect against myocardial infarction in animal studies by activating phosphatidylinositol-3 kinase (PI3K)/Akt and ERK1/2. However these pro-survival pathways are impaired in the diabetic heart. We investigated the ability of EPO to protect human atrial trabeculae from non-diabetic and diabetic patients undergoing coronary artery bypass surgery, against hypoxia-reoxygenation injury.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/17952111-12396724,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17952111-12796124,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17952111-12927817,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17952111-12960081,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17952111-14523037,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17952111-15059965,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17952111-15117842,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17952111-15169905,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17952111-15247477,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17952111-15611843,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17952111-15725950,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17952111-15883754,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17952111-15944807,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17952111-16046302,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17952111-16153943,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17952111-16781691,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17952111-17952110,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17952111-4056048,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17952111-8531217,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17952111-9302340,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17952111-9875214
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
0007-1188
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
153
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
50-6
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:17952111-Adult,
pubmed-meshheading:17952111-Aged,
pubmed-meshheading:17952111-Caspase 3,
pubmed-meshheading:17952111-Enzyme Activation,
pubmed-meshheading:17952111-Erythropoietin,
pubmed-meshheading:17952111-Female,
pubmed-meshheading:17952111-Heart,
pubmed-meshheading:17952111-Humans,
pubmed-meshheading:17952111-Male,
pubmed-meshheading:17952111-Middle Aged,
pubmed-meshheading:17952111-Mitogen-Activated Protein Kinase 1,
pubmed-meshheading:17952111-Mitogen-Activated Protein Kinase 3,
pubmed-meshheading:17952111-Myocardial Reperfusion Injury,
pubmed-meshheading:17952111-Phosphatidylinositol 3-Kinases,
pubmed-meshheading:17952111-Proto-Oncogene Proteins c-akt,
pubmed-meshheading:17952111-Recombinant Proteins
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Erythropoietin protects the human myocardium against hypoxia/reoxygenation injury via phosphatidylinositol-3 kinase and ERK1/2 activation.
|
|
pubmed:affiliation |
The Hatter Cardiovascular Institute, University College London Hospitals and Medical School, London, UK.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
